C. Mascaux (Bruxelles, Belgium), R. Buhl (Mainz, Germany)
Comparison of tumour markers in induced sputum and serum
B. Ozkan, C. Simsek, F. Okten, T. Eryilmaz (Ankara, Turkey)
|  |
Tumor markers in bronchial secretions and serum in patients with lung cancer
M. H. Kanakaki, P. Myrianthefs, N. K. Markou, K. Venetsanou, A. Damianos, B. Gorgoulis, H. Kittas, G. Baltopoulos (Athens, Greece)
| |
Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer?
E. Uzaslan, D. Ediger, M. Koc, F. Coskun, E. Rodoplu, O. Ozkubat, A. Ursavas, B. Erdogan, M. Karadag, E. Ege, O. Gozu (Bursa, Turkey)
| |
CD44v6 expression in tissue of patients with lung cancer
P. M. Lepper, C. Schumann, S. N. Weindel, M. Hetzel, G. Steinbach, P. Moller, S. Perner (Ulm, Germany)
| |
The value of CD44 and MMP-2 expression in non-small cell lung cancer
S. M. Alpar, N. Ucar, F. Demirag, Y. Agackiran, O. Orsel, B. Kurt (Ankara, Turkey)
| |
Her-2/neu expression in advanced non small cell lung carcinomas
O. A. Sukhoversha, V. V. Lizogubov (Dnipropetrovsk, Ukraine)
| |
Serum levels of vascular endothelial growth factor in lung cancer patients
A. S. Turgut, N. Ucar, S. Alpar, T. Bakirci, B. Dursun, B. Kurt (Ankara, Turkey)
| |
The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage (BAL) in lung cancer patients
B. Erdogan, E. Uzaslan, F. Budak, B. Oral, M. Karadag, D. Ediger, G. Goral, E. Ege, O. Gozu (Bursa, Turkey)
| |
The role of Pgp, MRP and LRP expression in chemotherapy response of small cell lung cancer
N. Triller, P. Korosec (Golnik, Slovenia)
| |
Apoptosis, tumor cell proliferation and angiogenesis as prognostic factor in lung cancer
E. A. Kogan, S. A. Demoura, S. I. Swets, V. L. Kovalenko (Moscow, Russia)
| |
Diagnostic value of type I collagen cross-linked N-telopeptide in bone metastasis of lung cancer
M. Tekesin, G. Ozkan, E. Altunkaynak, N. D. Bakan, A. Gur, G. Camsari (Istanbul, Turkey)
| |
Arg72Pro P53 gene polymorphism as a predisposing factor for non-small cell lung cancer (NSCLC) development
A. Szymanowska, E. Jassem, A. Borg, K. Holm, M. Perkowska, R. Dziadziuszko, W. Rzyman, G. Kobierska-Gulida, J. Limon, J. Jassem (Gdansk, Poland; Lund, Sweden)
| |
Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients
A. Szymanowska, E. Jassem, A. Borg, K. Holm, M. Perkowska, R. Dziadziuszko, W. Rzyman, G. Kobierska-Gulida, J. Limon, J. Jassem (Gdansk, Poland; Lund, Sweden)
| |
Thymidylate synthase (TS) polymorphism in non-small cell lung cancer (NSCLC) patients
E. Jassem, R. Rosell, M. Taron, R. Dziadziuszko, A. Szymanowska, P. Mendez, E. Martinez, G. Kobierska-Gulida, J. Skokowski, J. Jassem (Gdansk, Poland; Barcelona, Spain)
| |
Molecular detection of lung cancer using common-MAGE primer and -SSX primer
K. H. Lee, K. C. Shin, J. H. Chung, H. J. Park, Y. J. Jeon (Daegu, Gumi, South Korea)
| |
Assessment of lipid peroxidation and antioxidant capacity in pulmonary parenchyma and lung cancer tissue in non-small cell lung cancer
L. Y. Aydin, B. M. Berktas, A. Kiyici (Ankara, Konya, Turkey)
| |
Expression of sex hormone receptors in non-small cell lung cancer patients
E. Radzikowska, R. Langfort, D. Giedronowicz (Warsaw, Poland)
| |
Adenovirus-mediated interferon-β gene therapy combined with radiotherapy synergistically inhibits lung tumor growth in mice
R. Wiewrodt, M. Sebastian, J. Hast, A. Jovanovic, S. M. Albelda, R. Buhl (Mainz, Germany; Philadelphia, United States Of America)
| |
Interleukin-17 enhances the net angiogenic potential and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis
M. Numasaki, H. Takahashi, H. Sasaki (Sendai, Japan)
| |